Takeda Pharmaceutical/$TAK

1D1W1MYTD1Y5YMAX

About Takeda Pharmaceutical

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
Ticker
$TAK
Sector
Health
Primary listing
NYSE
Employees
47,029
Headquarters
Chuo, Japan
Website
www.takeda.com

TAK Metrics

BasicAdvanced
$61B
-
-$0.66
0.10
$0.49
2.55%

What the Analysts think about TAK

Analyst ratings (Buy, Hold, Sell) for Takeda Pharmaceutical stock.
Analyst projections of the future price of Takeda Pharmaceutical stock.

Bulls say / Bears say

The U.S. Food and Drug Administration approved Takeda and Protagonist’s rusfertide (Mimrylo) for polycythemia vera on August 28, 2026, with peak global sales projected between $1 billion and $2 billion (Yahoo Finance).
Takeda’s experimental immunoglobulin therapy for primary immunodeficiency disease met the primary endpoint in a pivotal Phase 2/3 trial in early May 2026, and the company plans to seek regulatory approvals in the U.S., EU, and Japan this fiscal year (Reuters via Yahoo).
Japan Credit Rating Agency assigned an AA- rating to Takeda’s bonds in a recent review, signaling an improved credit profile and potentially lower borrowing costs (Japan Credit Rating Agency).
Takeda's reported net profit for Q1 ended June 30, 2026 declined 8.9% year-on-year to JPY 113.2 billion, as higher finance and tax expenses weighed on quarterly earnings (MarketScreener).
A U.S. jury in Boston found Takeda liable for approximately $885 million in damages for delaying the launch of a generic version of its constipation drug Amitiza, exposing the company to significant reputational and financial risk (MarketScreener).
Takeda recorded an additional provision of JPY 402.5 billion in FY2025 earnings to cover estimated liabilities from the U.S. antitrust verdict, prompting a revision of its annual financial results (Stockopedia).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.

TAK Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

TAK News

AllArticlesVideos

Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems

Business Wire2 days ago

India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India

Reuters2 days ago

U.S. FDA Accepts New Drug Application Under Priority Review for Takeda's Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations

Business Wire6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.